Fmr LLC Grows Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Fmr LLC grew its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 3.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,944,831 shares of the biotechnology company’s stock after buying an additional 68,881 shares during the quarter. Fmr LLC owned 0.83% of ADMA Biologics worth $38,877,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. D. E. Shaw & Co. Inc. increased its stake in ADMA Biologics by 26.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after acquiring an additional 1,442,799 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of ADMA Biologics by 2.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after purchasing an additional 92,281 shares during the last quarter. Driehaus Capital Management LLC raised its holdings in shares of ADMA Biologics by 17.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock valued at $33,860,000 after buying an additional 447,743 shares in the last quarter. Renaissance Technologies LLC lifted its position in ADMA Biologics by 28.7% in the 2nd quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock worth $28,868,000 after buying an additional 575,100 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in ADMA Biologics by 11.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,401,533 shares of the biotechnology company’s stock worth $48,007,000 after buying an additional 249,412 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. HC Wainwright boosted their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Raymond James boosted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a research note on Friday, September 20th.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $19.82 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.64. The company has a market capitalization of $4.69 billion, a P/E ratio of 70.79 and a beta of 0.70. The stock has a 50 day moving average price of $19.10 and a two-hundred day moving average price of $15.76.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the prior year, the business posted $0.01 EPS. Analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Insider Transactions at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.70% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.